RTP Mobile Logo
What Urologists Want to Know: Addressing Current Questions and Controversies in the Management of Early and Advanced Prostate Cancer
Released August 2017

Proceedings from a CME symposium held at the 2017 American Urological Association’s Annual Meeting. Featuring perspectives from Drs Raoul S Concepcion, Leonard G Gomella, Daniel W Lin, David I Quinn and A Oliver Sartor. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

    Prostate cancer is the most frequently diagnosed cancer and the third leading cause of cancer death in men. As data have accumulated documenting the efficacy of a number of therapies before the standard introduction of chemotherapy, the needs of the practicing urologist have grown exponentially. Given that patients with prostate cancer could potentially receive multiple lines of therapy before chemotherapy, the urologist and his/her team in many instances may elect to or be called upon to extend their care of patients in the advanced disease setting. Additionally, urologists are often the first physicians to initiate discussions about and/or recommend treatment with cytotoxic therapy. As such, it seems quite clear that additional resources are necessary to assist these clinicians as they contend with the complexity of decision-making throughout the course of prostate cancer treatment.

    These video proceedings from a live CME symposium use the perspectives of leading genitourinary cancer experts to explore significant advances in the field of prostate cancer research. This CME activity will help urologists and other allied healthcare professionals with the formulation of up-to-date clinical management strategies for prostate cancer.


    • Review existing and emerging research data evaluating the use of novel biomarkers and gene signatures to refine the risk of recurrence for patients with localized prostate cancer, and use the results from available molecular assays to guide clinical decision-making.
    • Evaluate emerging clinical trial evidence with the use of available and investigational secondary hormonal agents in the management of nonmetastatic prostate cancer, and consider this information in the discussion of protocol and nonresearch treatment options.
    • Explore published research information on the use of cytotoxic therapy in the setting of hormone-sensitive advanced prostate cancer, and refer appropriate candidates for consultation with a medical oncologist to discuss the risks and benefits of this approach.
    • Compare and contrast the efficacy and safety of denosumab and bisphosphonates in the treatment and/or prevention of prostate cancer skeletal metastases.
    • Consider available research data and expert perspectives on the efficacy and safety of radium-223 chloride as monotherapy or in combination with other treatment modalities, and use this information to appropriately integrate this novel radiopharmaceutical agent into current nonresearch treatment algorithms.
    • Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic prostate cancer.
    • Counsel appropriately selected patients with prostate cancer about the availability of and participation in ongoing clinical trials.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Raoul S Concepcion, MD
    The Comprehensive Prostate Center
    Nashville, Tennessee

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Integra Connect; Speakers Bureau: Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Sanofi Genzyme.

    Leonard G Gomella, MD
    The Bernard W Godwin Professor of Prostate Cancer
    Chairman, Department of Urology
    Associate Director
    Jefferson Sidney Kimmel Cancer Center
    Clinical Director, Jefferson Sidney Kimmel 
    Cancer Center Network
    Editor-in-Chief, Canadian Journal of Urology
    Philadelphia, Pennsylvania

    Advisory Committee: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Pfizer Inc.

    Daniel W Lin, MD
    Professor and Chief of Urologic Oncology
    Department of Urology
    Bridges Endowed Professorship in Prostate Cancer Research
    University of Washington
    Seattle, Washington

    Consulting Agreement: Astellas Pharma Global Development Inc; Contracted Research: GenomeDx, Genomic Health Inc, MDxHealth.

    David I Quinn, MBBS, PhD
    Medical Director
    Norris Cancer Hospital and Clinics
    Head, GU Cancer Section
    Division of Cancer Medicine and Blood Diseases
    USC/Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee and Consulting Agreements: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Exelixis Inc, Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme.

    A Oliver Sartor, MD
    Medical Director, Tulane Cancer Center
    Laborde Professor of Cancer Research
    Professor of Medicine and Urology
    Tulane Medical School
    New Orleans, Louisiana

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Johnson & Johnson Pharmaceuticals, Medivation Inc, a Pfizer Company, OncoGenex Pharmaceuticals Inc, Sanofi Genzyme, Tokai Pharmaceuticals Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Endocyte Inc, Innocrin, Johnson & Johnson Pharmaceuticals, Sanofi Genzyme.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, a Pfizer Company, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genomic Health Inc and Sanofi Genzyme.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2017
    Expiration date: August 2018

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):